NTX-801
/ Nimbus Therap
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 26, 2025
Targeting CBL and CBLB ubiquitin ligases to exhaust cancer stem cells in metastatic breast cancer
(AACR 2025)
- "We generated a unique mouse model in which the C3(1)-TAg transgene drives mammary tumors known to resemble human triple-negative breast cancer (TNBC) and floxed-Cbl and Cblb genes can be inducibly deleted using tamoxifen (via CreERT2). Our results establish a tumor-intrinsic requirement of CBL/CBL-B to maintain breast cancer CSCs and add a critical second rationale for the use of chemical inhibitors of CBL/CBL-B as targeted therapeutics to counter BC recurrence and metastasis."
Cancer stem • Metastases • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CBL • CBLB
April 08, 2022
Nimbus Therapeutics Presents Preclinical Data on Cbl-b Inhibitor at AACR Annual Meeting
(Businesswire)
- "Nimbus Therapeutics...is sharing preclinical data, released today, on its Casitas B-lineage lymphoma b (Cbl-b) inhibitor, NTX-801, at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022, in New Orleans, LA....The inhibitor NTX-801 demonstrated strong immune cell activation and robust and statistically significant tumor growth inhibition in a mouse syngeneic tumor model."
Preclinical • Oncology • Solid Tumor
March 28, 2022
Nimbus Therapeutics to Present Update on Cbl-b Discovery Program at AACR 2022 Annual Meeting
(Businesswire)
- "Nimbus Therapeutics...announced that it will present preclinical data from its Casitas B-lineage lymphoma b (Cbl-b) program at the American Association for Cancer Research (AACR) 2022 Annual Meeting, being held April 8-13, 2022 in New Orleans, LA."
Preclinical • Hematological Malignancies • Lymphoma • Oncology
1 to 3
Of
3
Go to page
1